新型冠状病毒肺炎与胃肠疾病：当前见解与未来管理
COVID-19 and Gastrointestinal Disease: Current Insights and Future Management.
作者信息
Kopel Jonathan, Goyal Hemant
机构信息
Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Center for Interventional Gastroenterology at UT (iGUT), Department of Endoluminal Surgery & Interventional Gastroenterology, The University of Texas Health Sciences Center, 6431 Fannin Street, Houston, TX 77030, USA.
出版信息
J Clin Med. 2023 Apr 6;12(7):2727. doi: 10.3390/jcm12072727.
Abstract
The first case of coronavirus disease 2019 (COVID-19) was reported in Wuhan, Hubei Province, China, in December 2019, marking a pivotal moment in human history [...].
摘要
2019年12月，中国湖北省武汉市报告了首例2019冠状病毒病（COVID-19），这标志着人类历史上的一个关键时刻[...]。
相似文献
1
COVID-19 and Gastrointestinal Disease: Current Insights and Future Management.新型冠状病毒肺炎与胃肠疾病：当前见解与未来管理
J Clin Med. 2023 Apr 6;12(7):2727. doi: 10.3390/jcm12072727.
2
Ecological Study on Differences in COVID-19 Fatality among Wuhan, Rest of Hubei, and Rest of China.武汉、湖北省其他地区和中国其他地区 COVID-19 病死率差异的生态学研究。
J Epidemiol Glob Health. 2021 Mar;11(1):42-45. doi: 10.2991/jegh.k.200902.001. Epub 2020 Sep 10.
3
Trend Dynamics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission in 16 Cities of Hubei Province, China.中国湖北省16个城市严重急性呼吸综合征冠状病毒2（SARS-CoV-2）传播的趋势动态
Clin Epidemiol. 2020 Jul 2;12:699-709. doi: 10.2147/CLEP.S254806. eCollection 2020.
4
Risk estimation and prediction of the transmission of coronavirus disease-2019 (COVID-19) in the mainland of China excluding Hubei province.中国大陆（不含湖北省） 2019 年冠状病毒病（COVID-19）传播的风险估计和预测。
Infect Dis Poverty. 2020 Aug 24;9(1):116. doi: 10.1186/s40249-020-00683-6.
5
Gastrointestinal and Liver Manifestations in COVID-19 Population.COVID-19患者的胃肠道和肝脏表现
Middle East J Dig Dis. 2021 Oct;13(4):281-286. doi: 10.34172/mejdd.2021.236. Epub 2021 Sep 3.
6
[Risk assessment of exported risk of COVID-19 from Hubei Province].[湖北省新型冠状病毒肺炎疫情输出风险评估]
Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Apr 6;54(4):362-366. doi: 10.3760/cma.j.cn112150-20200219-00142.
7
Distribution of the COVID-19 epidemic and correlation with population emigration from Wuhan, China.新冠疫情的分布与中国武汉人口外流的相关性。
Chin Med J (Engl). 2020 May 5;133(9):1044-1050. doi: 10.1097/CM9.0000000000000782.
8
Estimating Risk for Death from Coronavirus Disease, China, January-February 2020.估算 2020 年 1-2 月中国新冠肺炎死亡风险。
Emerg Infect Dis. 2020 Jun;26(6):1251-1256. doi: 10.3201/eid2606.200233. Epub 2020 Jun 17.
9
Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019.与 COVID-19 暴露的医护人员心理健康结果相关的因素。
JAMA Netw Open. 2020 Mar 2;3(3):e203976. doi: 10.1001/jamanetworkopen.2020.3976.
10
Regional Differences in Epidemiological and Clinical Characteristics, Treatment, and Clinical Outcomes of COVID-19 in Wuhan and Remote Areas of Hubei Province.武汉与湖北省偏远地区新型冠状病毒肺炎流行病学和临床特征、治疗及临床结局的地区差异
Front Med (Lausanne). 2021 Jul 15;8:667623. doi: 10.3389/fmed.2021.667623. eCollection 2021.
本文引用的文献
1
Gut as an Alternative Entry Route for SARS-CoV-2: Current Evidence and Uncertainties of Productive Enteric Infection in COVID-19.肠道作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的另一条进入途径：2019冠状病毒病（COVID-19）中肠道感染的现有证据及不确定性
J Clin Med. 2022 Sep 26;11(19):5691. doi: 10.3390/jcm11195691.
2
Mechanisms Leading to Gut Dysbiosis in COVID-19: Current Evidence and Uncertainties Based on Adverse Outcome Pathways.COVID-19导致肠道微生物群失调的机制：基于不良结局途径的当前证据与不确定性
J Clin Med. 2022 Sep 14;11(18):5400. doi: 10.3390/jcm11185400.
3
Liver Function Tests in COVID-19: Assessment of the Actual Prognostic Value.新型冠状病毒肺炎的肝功能检查：实际预后价值评估
J Clin Med. 2022 Aug 1;11(15):4490. doi: 10.3390/jcm11154490.
4
Psychological Effects and Medication Adherence among Korean Patients with Inflammatory Bowel Disease during the Coronavirus Disease 2019 Pandemic: A Single-Center Survey.2019年冠状病毒病大流行期间韩国炎症性肠病患者的心理影响及药物依从性：一项单中心调查
J Clin Med. 2022 May 27;11(11):3034. doi: 10.3390/jcm11113034.
5
The Effects of COVID-19 on Clinical Outcomes of Non-COVID-19 Patients Hospitalized for Upper Gastrointestinal Bleeding during the Pandemic.新冠疫情期间新冠病毒病对因上消化道出血住院的非新冠病毒病患者临床结局的影响
J Clin Med. 2022 Apr 27;11(9):2461. doi: 10.3390/jcm11092461.
6
Assessment of Gastrointestinal Symptoms and Dyspnea in Patients Hospitalized due to COVID-19: Contribution to Clinical Course and Mortality.新型冠状病毒肺炎住院患者胃肠道症状和呼吸困难的评估：对临床病程和死亡率的影响
J Clin Med. 2022 Mar 25;11(7):1821. doi: 10.3390/jcm11071821.
7
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.全国性COVID-19-EII研究：西班牙炎症性肠病和COVID-19患者登记处（ENEIDA）的发病率、环境风险因素及长期随访
J Clin Med. 2022 Jan 14;11(2):421. doi: 10.3390/jcm11020421.
8
Acute Mesenteric Ischemia in COVID-19 Patients.新冠肺炎患者的急性肠系膜缺血
J Clin Med. 2021 Dec 30;11(1):200. doi: 10.3390/jcm11010200.
9
Liver Injury in Patients with Coronavirus Disease 2019 (COVID-19)-A Narrative Review.2019冠状病毒病（COVID-19）患者的肝损伤——一项叙述性综述
J Clin Med. 2021 Oct 28;10(21):5048. doi: 10.3390/jcm10215048.
10
FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19.FibroScan-AST评分可预测COVID-19住院患者30天死亡率或机械通气需求。
J Clin Med. 2021 Sep 24;10(19):4355. doi: 10.3390/jcm10194355.
Zotero 插件